TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15249 · Oct 26

#html#ech#fail2ban#http#mixed#ml_dsa_65#ml_kem_768#post_quantum#reality#shadowsocks#shadowsocks2022#tls#trojan#tunnel#vless#vmess#wireguard#x25519#xtls_rprx_vision#xtls_rprx_vision_udp443 3X-UI is an easy-to-use, open-source web control panel for managing Xray-core VPN servers. It supports many VPN protocols like VMess, VLESS, Shadowsocks, Trojan, and WireGuard, letting you configure, monitor traffic, manage users, and set limits through a simple web interface. It includes features like automatic SSL certificates, traffic statistics, multi-user support, and security options such as firewall rules and IP bans. This makes managing VPN servers faster, more secure, and accessible even if you are not an expert, helping you control your VPN setup efficiently and safely. https://github.com/MHSanaei/3x-ui

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment